About Libtayo Libtayo is a fully-human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T-cells. By binding to PD-1, Libtayo has been shown to block cancer cells from using the ...

Sanofi and Regeneron’s Libtayo is on a roll with its second FDA nod in just two weeks. And the latest green light breaks the PD-1 inhibitor out of its skin cancer comfort zone and into the competitive ...

It's often a bad sign when a clinical trial stops early. Not so for Sanofi and Regeneron Pharmaceuticals. On Thursday, the partners said they were pumping the brakes on a pivotal study of a ...

Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50% In the overall trial ...

"The Libtayo clinical development program, as monotherapy or in combination with either conventional or novel therapies, focuses on the real-world challenges of patients confronting difficult-to-treat ...

Approval based on a Phase 3 trial demonstrating Libtayo significantly improved overall survival compared to chemotherapy in advanced NSCLC that included challenging-to-treat patient populations ...

The recent FDA approval of Libtayo for advanced non-small cell lung cancer added yet another option for the treatment of patients with the disease. In recent years, there has been a “renaissance of ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the presentation of positive results from the Phase 3 trial investigating the PD-1 inhibitor Libtayo (R) (cemiplimab) in ...

Libtayo significantly reduced the risk of death for patients with recurrent or metastatic cervical cancer. If the FDA approves Libtayo as a treatment for cervical cancer, Regeneron could see around ...

TARRYTOWN, N.Y., March 29, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Commission (EC) approved Libtayo® (cemiplimab) in combination with ...